Antibody-drug conjugates (ADCs) are fulfilling the promise of targeted therapy with meaningful clinical success. An intense research effort is directed towards improving pharmacokinetic profiles, toxicity and chemical stability of ADCs. The majority of ADCs use amide and thioether chemistry to link potent cytotoxic agents to antibodies via endogenous lysine and cysteine residues. While maleimide-cysteine conjugation is used for many clinical stage ADC programs, maleimides have been shown to exhibit some degree of post-conjugation instability. Previous research with site-directed mutagenic incorporation of cysteine residues for conjugation revealed that the stability of the drug-antibody linkage depends on the site of conjugation. Here we report on a collection of engineered cysteine antibodies (S239C, E269C, K326C and A327C) that can be site-specifically conjugated to potent cytotoxic agents to produce homogenous 2-loaded ADCs. These ADCs confirm that site of conjugation impacts maleimide stability and present a novel mechanism of thioether stabilization, effectively unlinking stability from either local chemical environment or calculated solvent accessibility and expanding the current paradigm for ADC drug-linker stability. These ADCs show potent in vitro and in vivo activity while delivering half of the molar equivalent dose of drug per antibody when compared to an average 4-loaded ADC. In addition, our lead engineered site shields highly hydrophobic drugs, enabling conjugation, formulation and clinical use of otherwise intractable chemotypes.
Introduction
Antibody-drug conjugates (ADCs) hold great promise, especially in oncology, as the next generation of targeted therapies (Polakis, 2016) . Leveraging the immunologic specificity of antibodies to deliver highly potent cytotoxic agents to diseased tissue both improves antitumor activity and limits off target toxicities. This approach has now been used successfully in four FDA-approved ADCs, namely brentuximab vedotin, inotuzumab ozogamicin, gemtuzumab ozogamicin and ado-trastuzumab emtansine (Verma et al., 2012; Younes et al., 2010) , and is the focus of numerous pre-clinical studies and clinical trials. For these studies, the vast majority of conjugates take advantage of endogenous nucleophiles such as the ε-amino group of lysine or the sulfhydryl of cysteine for chemical attachment. This approach results in a mixed conjugate with a distribution of drug to antibody stoichiometries. A better understanding of the chemical properties of the drug/ linker/antibody is necessary to improve therapeutic impact and to extend the utility of this class of molecules (Doronina et al., 2003; Lyon et al., 2014; Polson et al., 2007) . Studies show that limiting the number of drugs per antibody and defining the site of attachment may improve the activity and reduces the toxicological liability of this class of therapeutics (Hamblett et al., 2004; McDonagh et al., 2006) . Further work indicates significant differences in chemical and biochemical properties of ADCs depending on conjugation site and could dramatically impact pharmacodynamic properties in patients (Shen et al., 2012; Strop et al., 2013) .
A variety of chemical strategies have been employed to conjugate protein toxins and cytotoxic drugs to antibodies, including reactions between amines and N-hydroxysuccinimide (NHS) esters, and sulfhydryls with maleimides (Carter and Senter, 2008) . This latter reaction, in particular, is often used and offers tremendous benefits to conjugation chemistry, including exquisite selectivity and rapid reaction rates under aqueous conditions compatible with maintaining protein structure and activity (Chari et al., 2014; Hermanson, 2008) .
In addition to the chemical benefits outlined above, sulfhydryl reactions offer the benefit of reduced heterogeneity when the interchain disulfides are reduced to provide the acceptors for conjugation. In the case of IgG 1 antibodies, only eight potential sites can be derivatized in contrast to >30 sites for lysine-directed strategies. This benefit can be further enhanced by site-directed mutagenic introduction of cysteine residues into each of the two heavy or light chains, allowing for the production of completely defined conjugates with a specific number of drugs/mAb (Junutula et al., 2008) . This allows for uniform drug loading with no contaminating unconjugated or over-conjugated mAb and precisely defined molecular structures.
There is a however a drawback to maleimide conjugations, namely that varying degrees of reversibility have been reported in the literature. Research has shown that conjugated drug can be shed from the antibody via a retro-Michael elimination reaction and lost to scavenging free sulfhydryls in the serum, most notably cysteine 34 in albumin (Alley et al., 2008; Baldwin and Kiick, 2011; Ryan et al., 2011) . The thioether bond is stabilized via a competing hydrolysis reaction that results in an opening of the thiosuccinimide ring to form an adduct that is resistant to the elimination reaction ( Fig. 4A) (Lyon et al., 2014; Tumey et al., 2014) . Studies of engineered ADCs have shown that the stability of the antibody-drug bond can vary depending on the site of substitution (Shen et al., 2012) . Low stability was associated with reduced in vivo activity, demonstrating that a stable linkage is a desirable feature in an ADC. Shen et al. also noted that the rates of maleimide hydrolysis varied across sites and ascribed the differences to local electrostatic environment and solvent accessibility affecting rates of maleimide hydrolysis.
In order to define further the interplay between the site of conjugation and the resulting physicochemical properties of an ADC, we have prepared a series of engineered cysteine (EC) mAbs with substitutions clustered in the hinge region of the C H 2 domain. We selected sites with diverse calculated solvent accessibility and electrostatic potentials. ADCs prepared from these engineered antibodies exhibit varying stability with no correlation to hydrolysis rates or local environment. The drug solvent exposure (determined by HIC) was a strong predictor of stability and suggests an alternate mechanism for location-dependent stability.
Materials and Methods

Structural analysis and molecular modeling
Protein database files of an intact antibody and of a human Fc region bound to Fc gamma receptor 3 (accession numbers 1HZH and 1E4K, respectively) were used in analysis. Pymol (Schrodinger) was used to generate molecular model figures. Electrostatic calculations were carried out using APBS (Baker et al., 2001 ) and colored to make +65 kT/e blue and −65 kT/e red. Solvent accessibility calculations were carried out using GETAREA (Fraczkiewicz and Braun, 1998) .
Conjugate preparation
Humanized anti-CD70 (h1F6) (McEarchern et al., 2008) engineered with additional heavy chain cysteine residues were conjugated to non-cleavable auristatin, maleimidocaproyl monomethylauristatin F (mcMMAF), and protease-cleavable pyrrolobenzodiazepine, or sandramycin (Biomar) drug-linkers following protocols described previously (Jeffrey et al., 2013) . Briefly, antibodies were fully reduced by adding 10 equivalents of tris(2-carboxyethyl)phosphine (TCEP) and 1 mM EDTA and adjusting the pH to 7.4 with 1 M Tris buffer (pH 9.0). Following 1 h incubation at 37°C, the reaction was cooled to 22°C and 30 equivalents of dehydroascorbic acid were added. The pH was adjusted to pH 6.5 with 1 M Tris-HCl buffer (pH 3.7) and the oxidation reaction was allowed to proceed for 1 h at 22°C. This resulted in reformation of native disulfides, but left the engineered heavy chain cysteines in the reduced state and available for conjugation. The pH of the solution was then raised again to pH 7.4 by addition of 1 M Tris buffer (pH 9.0). Conjugation was then carried out by the addition of 2.5 equivalents of the drug-linker, and the reaction was allowed to proceed at 22°C for 30 min. The resulting conjugate was purified by gel filtration chromatography using a disposable PD-10 column (GE Healthcare). The degree of drug loading and site of drug attachment was determined by reducing the ADC with dithiothreitol followed by HPLC analysis on a PLRP column and integration of the heavy and light chain components (Sun et al., 2005) . The extent of aggregation was determined by size exclusion chromatography.
EC site conjugation confirmation
Conjugated antibodies were subjected to protease treatment with endoproteinase Glu-C (Sigma-Aldrich). Digestion with Glu-C resulted in liberation of the Fc fragment cleaved C-terminal of the hinge cysteines at position 233. Mass spectrometric analysis of this Fc fragment showed an increase of 926 daltons over similarly treated, unconjugated, EC mutant Fc fragments.
ADC hydrophobicity analysis
ADCs were diluted in 5 M NaCl to a final concentration of 5 mg/ mL. 100 μg were then injected over a Butyl-NPR, 4.6 × 35 mm, 2.5 μ column mounted on a Agilent 1100 HPLC in running buffer A (25 mM KPi and 1.5 M (NH 4 ) 2 SO 4 at pH 7.0). Elution times for the 2 loaded species were measured during a gradient lasting 12 min transitioning from 100% buffer A to 100% buffer B (25 mM KPi, pH 7.0/25% IPA).
Ex vivo drug-linker stability
IgG was removed from rat plasma (Bioreclamation IVT) by incubation with Protein A resin (ProSepA, Millipore), rotation overnight at 4°C, followed by filtration to remove the resin (Ultrafree-MC Centrifugal Filter, Millipore). ADCs were spiked into IgG-depleted plasma (0.25 mg/mL). Aliquots (200 μL) were removed immediately (t = 0 d) and the remaining samples were incubated at 37°C for up to 7 days. At relevant time points, test article and an internal standard were extracted and digested. A tetrapeptide product corresponding to N-terminal amino acids from MMAF was purified using solid phase extraction and quantified with reference to a standard by quadrupole-time-of-flight (QTOF) mass spectrometry.
Ex vivo maleimide hydrolysis
IgG was removed from rat plasma (Bioreclamation IVT) by incubation with protein A resin (ProSepA, Millipore), rotating overnight at 4°C, followed by filtration to remove the resin (Ultrafree-MC Centrifugal Filter, Millipore). ADCs were spiked into IgG-depleted plasma (0.25 mg/mL). Aliquots (500 μL) were removed immediately (t = 0 d) and the remaining samples were incubated at 37°C for 7 days. Each sample (500 μL) was rotated with 300 μL ProSepA resin to capture ADC (50% PBS slurry, 4°C overnight) and then filtered through Ultrafree-MC spin cups (1 min, 11 000 × g). The resinbound ADC was washed with PBS (3 × 500 μL) and eluted with 300 μL IgG elution buffer (Thermo Scientific) into 30 μL 1 M Tris pH 8. A sample of each eluate (100 μL) was treated with 1 μL PNGase F (500 U/μL, New England Biolabs) and 5 μL LysC (0.1 μg/ μL, Promega) at room temperature for 30 min, followed by 37°C for 25 min, and subsequent addition of 100 mM dithiothreitol (10 μL) with further 15 min incubation at 37°C. The samples were examined using LC-MS via PLRP-S chromatography and electrospray ionization QTOF mass spectrometry. Data was deconvoluted using the MaxEnt1 function in MassLynx 4.0. Peak heights of deglycosylated HC Fc plus mcMMAF and deglycosylated HC Fc plus mcMMAF plus water were used for calculation of percent hydrolyzed druglinker. The cells were incubated for 1 h with 600 nM AlexaFluor-647 labeled wild-type m1F6 and increasing concentrations (from 0.19 nM to 600 nM) of unlabeled mutants or wild-type ADCs. Cells were pelleted and washed 3 times with PBS. The cells were then pelleted and resuspended in 125 μL of PBS/BSA. Fluorescence was analyzed by flow cytometry, using percent of saturated fluorescent signal to determine percent labeled antibody bound and to subsequently extrapolate the EC 50 by fitting the data to a sigmoidal doseresponse curve with variable slope.
Competition binding
In vitro cytotoxicity activity assay
The 786-O cells were obtained from the American Type Culture Collection and propagated in culture conditions recommended by the manufacturer. Cells were plated in 150 μL growth media per well into black-sided clear-bottom 96-well plates (Costar, Corning). About 24 h later, drug stocks were titrated as 5-fold serial dilutions producing 8-point dose curves and added at 50 μL per well in duplicate. Cells were then incubated for 96 h at 37°C, 5% CO 2 . Cytotoxicity was measure by incubating with 100 μL Cell Titer Glo (Promega) solution for 0.5 h, and then luminescence was measured on an EnVision Xcite plate reader (Perkin Elmer). Data was processed with Excel (Microsoft) and GraphPad (Prism) to produce dose-response curves and IC 50 values were generated and data collected.
In vivo activity studies
To establish the 786-O model, 5 × 10 6 cells were implanted into the right flank of athymic nu/nu female donor mice (Harlan). When donor tumors were~500 mm 3 [(L × W 2 )/2], mice were euthanized, tumors were aseptically excised, and~0.5 × 0.5 mm fragments were loaded into a sterilized 13-gauge trochar for implantation into anesthetized mice. When tumors reached~100 mm 3 , mice were randomly allocated to treatment groups and dosed via intraperitoneal injection at a single time point with 10 mg/kg ADC. Tumors were measured twice weekly, and volumes were calculated using the formula V = (L × W 2 )/2. Animals were euthanized when tumors reached~1000 mm 3 . Tumor volume was calculated using the formula (A × B 2 )/2, where A and B are the largest and second largest perpendicular tumor dimensions, respectively. Mean tumor volume and weight of mice were monitored and mice terminated when the tumor volume reached 1000 mm 3 .
Results
Site selection
We have conjugated drugs to reduced interchain disulfide bonds on more than 1000 antibodies and found that this conjugation minimally disrupts antibody structure. Given this experience, we sought sites in the C H 2 domain of the heavy chain which were proximal to the hinge region, solvent accessible (to permit contact between the maleimide and the sulfhydryl of the reduced cysteine) and unlikely to interfere with existing disulfide bond patterns or to destabilize structural elements. We chose sites that satisfied multiple criteria: (i) located within 20 Å of endogenous cysteines involved in interchain disulfide bond formation; (ii) side chain orientated towards the solvent; (iii) located at least 10 Å from native cysteines or the symmetry-related EC located on the other heavy chain pair (Fig. 1A) ; and (iv) lack of involvement in stabilizing secondary structural elements. These in silico criteria were satisfied by over 15 sites; however, many of these mutants expressed at very low levels, displayed unfavorable product quality properties or were not amenable to conjugation. The mutations described (Fig. 1A) here (S239C, E269C, K326C and A327C in the EU numbering system of Kabat) expressed well, had low levels of aggregate upon purification, contained a glycosylation profile similar to the wild-type antibody, as assessed by mass spectrometry, and could be conjugated to the introduced sites with a homogeneous drug load near two per antibody. All mutants retained wild-type affinity for FcγRI (CD64), while some, including S239C, displayed reduced affinity for FcγRIII (CD16), data not shown. Unless otherwise noted, results describe mcMMAF conjugated ADCs.
Conjugation product
In order to site-specifically conjugate drug-linkers to the introduced cysteine residues in the EC mAbs, we employed a protocol described by Jeffrey et al. (2013) . Antibody-mcMMAF conjugates were prepared and analyzed by variety of methods. Analysis of intact ADCs using HPLC and mass spectrometry confirmed a uniform population of ADCs with~2 drugs per mAb as expected (Fig. 2) ; in contrast wild-type mAbs do not incorporate any drug-linker under these conditions. In order to confirm the site specificity of the conjugation reaction, we compared the molecular weight of the Fc region of naked antibodies and ADCs prepared from either wild-type or mutant mAbs using endoproteinase Glu-C. Endoproteinase Glu-C cleaves C-terminal to the hinge interchain disulfides, leaving the EC as the likely conjugation position, later confirmed by peptide mapping (data not shown). The mass spectra (Fig. 2) demonstrate that only the mutant Fc regions incorporate a drug-linker and that the introduced cysteine (S239C) is the only site of conjugation. Similar results were seen with all of the EC antibodies and mass spectral analysis of the corresponding Fabs showed that all endogenous cysteines were present as disulfide bonds and had not been conjugated to the drug-linker (data not shown).
To determine EC mAb compatibility with highly lipophilic drugs, we conjugated either wild-type antibodies or EC mAbs to two hydrophobic DNA alkylating agents: pyrrolobenzodiazepine (Jeffrey et al., 2013) and sandramycin (Fig. S1) . When conjugated to endogenous cysteines as average four loads, the resulting ADCs demonstrate drug-dependent aggregation of approximately 20% and 19%, respectively. When conjugated as homogeneous two loads to the S239C EC mAb, the aggregation in both ADCs was reduced to <2% (Fig. 5) .
ADC binding and activity
We assessed the impact of the introduced cysteine/drug-linker on the binding of the mAb to its antigen. We used a conventional competition binding assay: a fixed concentration of fluorescently labeled parental antibody was titrated with increasing concentrations of non-labeled mutant or parental antibody and applied to antigen expressing cells. The concentration at which the competitor antibody reduces the fluorescent signal by 50% is reported as the IC 50 in Table I . The wild-type and cysteine mutants are identical within the error of the measurements indicating that cysteine substitutions and subsequent conjugation have no effect on engagement of the target by the ADC. In addition to measuring relative affinities of this collection of ADCs, we examined the cytotoxic effect that they have on antigen expressing cells, Table I . Surprisingly all mutant ADCs had similar potency to the wild-type ADC when incubated with CD70 positive cells, despite the fact that nominal drug dose for the mutant ADCs was only half that of the wild-type ADC.
In vivo antitumor activity of ADCs
In a single dose 786-O in vivo efficacy model (Fig. 3) , all ADCs had a significant impact on growth of the tumor when compared to untreated mice. However, there was a difference in performance between the mutants. Out of the mutants, 2-loaded S239C showed the best tumor growth inhibition, delaying tumor growth for~25 days, similar to the wild-type 4-load ADC. While A327C was slightly less effective than S239C (delaying tumor growth for 10 days), it outperformed E269C and K326C which had identical activities and only delayed tumor growth for~5 days.
Maleimide stability
As we have previously reported (Alley et al., 2008) , maleimides used to conjugate cytotoxic agents to antibodies can undergo a retroMichael reaction that results in release of the drug over time when incubated in animal plasma. To examine the stability of maleimides conjugated to ECs, we incubated conjugates in rat plasma for 7 days and analyzed samples for drug loss over that time course (Fig. 4) . We found that the propensity of the maleimide to undergo retro-Michael loss of the drug conjugate depended on the site of conjugation, with the wild-type 4-drug loaded ADC being the most susceptible and losing roughly 40% of its drug load over the 7 days. In comparison, S239C was the most stable, losing less than 10% over the same period. A327C, E269C and K326C showed intermediate levels of drug loss with 21%, 28% and 26%, respectively. Fig. 1 (A-C) Sites selected for conversion to cysteine were near the hinge region of the antibody, differed in calculated solvent accessibility and had no unifying electrostatic character. (A) Sites were first identified on the Fc fragment proximal to the hinge between the Fc and the Fab (left panel). These sites coincide with the CD16 binding sites as shown in the co-crystal structure 1E4K (center panel). Relative orientations of the Fc, Fabs, and CD16 can be seen in the model generated from docking CD16 onto the intact antibody crystal structure 1HZH (right panel). (B) Using 1HZH as a template, selected residues were converted to cysteine in silico and solvent accessibility for the new residue was calculated, showing a 5-fold difference between sites. (C) Electrostatic potential was calculated for the modeled in silico mutants and projected on the molecular surface. These sites showed no consistent trend in either highly acidic or basic elements near the engineered site of conjugation
Thiosuccinimide hydrolysis
Hydrolysis of the thiosuccinimide ring that results from maleimidethiol conjugation prevents the retro-Michael reaction and can be used to stabilize ADCs, leading to improved in vivo characteristics (Lyon et al., 2014; Shen et al., 2012; Tumey et al., 2014) . To test if the chemical microenvironment around the introduced conjugation sites was impacting hydrolysis rates, we performed mass spectral analysis of the Fc fragment produced using LysC from an antibody incubated in rat plasma for 7 days. Pre-incubation samples showed a consistent amount of maleimide hydrolysis (~15%), indicated by an increase in mass of~20 Da, for all mutant ADCs. Postincubation samples had dramatically different levels of additional Note: To quantify relative binding affinities, a fixed concentration of fluorescently labeled parental antibody was titrated with increasing concentrations of non-labeled mutant or parental antibody and applied to antigen expressing cells. The concentration at which the competitor antibody reduces the fluorescent signal by 50% is reported as the IC 50 . To assess in vitro activity, increasing concentrations of ADC were applied to antigen expressing cells. The concentration of ADC that gives half-maximal response is reported as the EC 50 . Fig. 3 In vivo activity of naked antibody, native 4-loaded ADC and EC antibodies. Antibodies were tested for activity in a single 10 mg/kg dose 786-O xenograft experiment. The 2-loaded S239C EC outperformed the native 4-loaded and all other EC mutant ADCs ring opening: 7%, 9%, 61% and 65%, respectively, for S239C, A327C, E269C and K326C (Table II) . This result suggests an inverse correlation between stability and hydrolytic rate enhancement by the drug-linker's chemical microenvironment and is an opposite trend to what has been observed with other sites (Shen et al., 2012) .
Biophysical characterization of conjugation sites
In order to investigate the origin of these differential rates of hydrolysis and stabilization of the thiosuccinimide bond, we looked at several different attributes of the engineered conjugation sites: (i) the electrostatic environment surrounding the conjugation sites (Fig. 1C) ; (ii) calculated solvent accessibility of EC (Fig. 1B) ; and (iii) apparent hydrophobicity of each of the engineered ADCs (Table II) .
Local charged residues might promote or prevent proton abstraction and result in stabilization or elimination of the maleimide conjugate. We therefore analyzed the solvent accessible surface of the engineered Fc domains models by electrostatic potential. Visual inspection of these potentials surrounding the conjugation site showed no consistent placement of ionizable residues that could promote ring opening in the K326C and E269C ADCs. In fact, these introduced cysteines are in basic and acidic environments, respectively, and exhibited no difference in stability or susceptibility to hydrolysis. Nor did we find charged residues that could stabilize S239C and A327C, which are also in basic and acidic environments, respectively.
Conjugate hydrolysis requires accessibility of solvent molecules to the carbonyl atoms of the thiosuccinimide. It is possible that the maleimide conjugated at position 239 is simply shielded from the solvent and cannot participate in such a reaction. To determine whether solvent accessibility to conjugation sites predicted propensity of thiosuccinimide hydrolysis, we calculated the Connolly surface of in silico generated models. We found no correlation between exposed surface area and rates of hydrolysis (Fig. 1B) . However, when using hydrophobic interaction chromatography (HIC), we observed that in this relatively small collection of engineered ADCs, those that are quickest to hydrolyze (E269C and K326C) also exhibit the greatest apparent hydrophobicity.
Discussion
At least 70 ADCclinical trials are currently open and recruiting patients. Most use ADCs employing amide/NHS linkages or thioether/maleimide chemistry to conjugate cytotoxic payloads to endogenous lysine and cysteine residues, respectively. While these strategies approximate an ideal ADC (i.e. one that employs completely stable conjugation and linker technology, confers specificity and increases the therapeutic index) they still result in heterogeneity and, for maleimides, a degree of drug-linker instability. Antibodies with introduced cysteines, dubbed Thiomabs (Junutula et al., 2008) , that can be employed for the site-specific conjugation of cytotoxic agents have been reported by others. Studies of these introduced cysteine antibodies suggest a mechanism of stabilizing conjugates that invokes moderate solvent accessibility and a basic local chemical environment to hydrolyze the thiosuccinimide ring and prevent loss of conjugate via the retro-Michael reaction. More recently, Fig. 4 (A, B) ADC maleimide stability in plasma. (A) Step 1 in the schematic shows the reversible Michael addition used to conjugate antibody and drug-linker.
Step 2 illustrates a potential hydrolysis reaction that stabilizes the conjugate and prevents loss of the drug-linker. (B) Time course showing loss of the conjugated drug via the retro-Michael reaction during incubation of the ADC with rat plasma. The 2-loaded S239C EC is more stable than the native 4-loaded and all other EC mutant ADCs. Terminal % drug load relative to t = 0 h for each construct is shown in others have reported similar results on a more diverse collection of introduced cysteine antibodies (Tumey et al., 2017) . Here we report the generation of EC antibodies that produce homogenous 2-loaded ADCs and that are nearly 100% stable when incubated in plasma. Unlike the earlier reports with Thiomabs (Shen et al., 2012) , ring hydrolysis in these stabilized EC ADCs is very slow, indicating the presence of an alternative mechanism for slowing the rate of maleimide elimination. The observed trends in ADC stability correlate, albeit in a small collection of mutants, with apparent hydrophobicity as measured by HIC, suggesting chemical sequestration as an additional means to confer stability without catalyzing thiosuccinimide hydrolysis. EC sites were selected from a subset of residues proximal to the hinge, at ≥10 Å from endogenous or ECs on the same or paired heavy chain. ADCs can be produced from EC mAbs in near quantitative yield, with drug-linked only to the engineered sites and not to the endogenous cysteines (Fig. 2) . The EC sites are >50 Å distant from the antibody complementarity-determing regions (CDRs) and, as expected, did not interfere with antigen binding (Table I) . These antibodies expressed with expected titers and were not prone to aggregation during purification and conjugation. The 2-loaded ADCs tested here have nearly identical in vitro potencies as wild-type 4-loaded ADCs, despite on average delivering half of the cytotoxic payload per antibody.
During in vivo experiments, we saw strikingly different performance of the EC mAb ADCs. The most active site was S239C, which was equivalent or slightly better than wild-type ADC. Given these results, we explored the biophysical differences between the conjugates that might explain their levels of activity. In agreement with previous publications, we found that the various conjugates demonstrated significantly different rates of drug loss when incubated in plasma. In contrast to an earlier published mechanism of stabilization and in agreement with more recent work (Tumey et al., 2017) , these trends in drug-linker stability were unrelated to the chemical environment surrounding the conjugation site or modeled solvent accessibility, and further, the observed extent of thiosuccinimide ring opening was lowest for the most stable EC mAb ADCs. In addition, the extent of hydrophobicity imparted to the ADC by the addition of drug was inversely related to stability and could be used to predict rank order of activity and retro-Michael reaction rates. The apparent hydrophobicity of each ADC by hydrophobic interaction chromatography (HIC) may be indicative of the extent to which the drug-linker is accessible to solvent, and therefore able to interact with the chromatographic stationary phase. These data support the expansion of the current mechanistic paradigm for stable maleimide conjugates to include sites that are not stabilized by maleimide hydrolysis, but rather a novel mechanism whereby potentially hydrolysis is slowed by exclusion of solvent molecules by surrounding amino acids.
Recently, much attention has been given novel site-specific conjugation technologies. Many of these techniques provide their own challenges, including incorporation of unnatural amino acids and post-purification enzyme modification and extensive preclinical and clinical validation of these techniques has yet to be achieved. EC sites have been investigated for over 20 years as an approach to improve antibody activity and introduce conjugation sites (Lyons et al., 1990; Shopes, 1992; Stimmel et al., 2000) . The methods for production of these engineered antibodies have been developed, although clinical proof-of-concept remains to be demonstrated.
Though, given the significant clinical success of conventional conjugates, the need for site-directed technologies to be employed with the auristatin or maytansine chemotypes is not immediately clear. The argument has been made that using site-specific conjugation technologies might increase the therapeutic index for a given target and antibody combination. However, we believe the most tangible impact of the EC mAbs is in enabling potent hydrophobic chemotypes that are incompatible with conventional conjugation methods. As evidence, we have employed the EC mAbs to produce conjugates using the highly hydrophobic pyrrolobenzodiazepine and sandramycin cytotoxins. These drugs, when conjugated to wild-type antibodies as average 4-loaded ADCs using conventional methods, produce an unacceptable level of aggregation (Fig. 5) . However, Fig. 5 Improvement of aggregation prone ADCs. (A) Size exclusion chromatography of pyrrolobenzodiazepine ADCs. Conventionally conjugated, average four-loaded ADCs (black), show greater than 20% aggregation, whereas the homogenous two-loaded EC ADC has less than 2% aggregation. (B) Size exclusion chromatography of sandramycin ADCs. Conventionally conjugated, average four-loaded ADCs (black), show greater than 18% aggregation whereas the homogenous two-loaded EC ADCs have less than 2% aggregation when conjugated to the S239C site, the resulting ADCs are largely monomeric and are well behaved in all analytic assays. As such, the EC mAb site, S239C, is the antibody platform for three programs currently in the clinical phase of testing
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